EU Green Light for Dostarlimab in Some Endometrial Cancers EU Green Light for Dostarlimab in Some Endometrial Cancers

A new PD-1 antagonist, dostarlimab, has been recommended for approval for use in some women with advanced/recurrent endometrial cancer.International Approvals

Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news